In current trading, HeartBeam Inc. (NASDAQ: BEAT) shares are up 26.05 percent to $5.71 after the company announced its product portfolio. The stock closed at $4.53 in the previous session.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
What are the latest developments in the portfolio of BEAT?
By providing clinically relevant diagnostic information to patients and clinicians, HeartBeam (BEAT) has expanded its product portfolio pipeline to meet the growing market for cardiac device wearable technology. As a result of the product pipeline advancement, HeartBeam will be able to add arrhythmia detection capabilities to address the multibillion-dollar global market for monitoring atrial fibrillation and other arrhythmias.
Based on recent patents issued by BEAT, the broader product portfolio enables:
- As part of BEAT’s regulatory portfolio, BEAT introduces a 3-lead 3D vector electrocardiogram (VECG) that records cardiac activity X,Y,Z and displays the signals for clinician review, the HeartBeam AIMIGo 3L. A 510(K) submission is scheduled for Q4 2022 to the United States Food and Drug Administration.
- To provide clinicians and patients with an optional monitoring solution based on HeartBeam’s platform via smartwatch connectivity in future products.
- Implementing recently issued patents for enhanced diagnostic accuracy in the AIMIGo 12L device for 510(K) submission to the FDA in Q2 2023, along with atrial fibrillation detection capability.
A significant development for BEAT, smartwatch connectivity extends the company’s portfolio by allowing 24/7 heart monitoring. With its breakthrough AIMIGo solution, HeartBeam anticipates its overall system will provide cardiac patients with a new and much higher level of diagnostic capability. As BEAT strives to bring comprehensive cardiac care to patients anywhere and anytime, it will continue to make steady progress. For 2023, a critical component is being procured to enable the Company to meet its planned production quantities for AIMIGo devices.
Which strategy will be used to leverage BEAT?
The addition of automated atrial fibrillation detection and smartwatch connectivity will significantly enhance HeartBeam (BEAT) AIMIGo heart attack solution. A significant and established market for atrial arrhythmia detection has been added to BEAT’s AIMIGo platform, making it a significant step forward.
